Use of the Fractal Dimension to Differentiate Epithelium and Connective Tissue in Oral Leukoplakias

Oral leukoplakia (OL) is considered one of the most common potentially malignant oral disorders (OPMD), with a verified increased risk of developing oral cancer. The identification of the dysplasia grade (low-high) is the only consolidated factor used to evaluate this risk. The objective of this stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2022-05, Vol.14 (11), p.2697
Hauptverfasser: Guerrero-Sánchez, Yolanda, Gómez García, Francisco, Chamorro-Petronacci, Cintia M, Suárez-Peñaranda, José M, Pérez-Sayáns, Mario
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Oral leukoplakia (OL) is considered one of the most common potentially malignant oral disorders (OPMD), with a verified increased risk of developing oral cancer. The identification of the dysplasia grade (low-high) is the only consolidated factor used to evaluate this risk. The objective of this study was to verify the role of the fractal dimension (FD) in assessing this dysplasia. To begin, 29 OL and 10 normal oral mucosa (NOM) biopsies were retrieved for FD analysis of the epithelial ( ) and the connective ( ) tissue. In the OL group, the median value of dime is higher (1.67, IQR = 0.12) than for the NOM group (1.56, IQR = 0.08), with statistically significant differences (Wilcoxon test, = 0.0031). There were no differences in relation to dimc. Significant differences were observed between the non-dysplasia vs. high-grade ( = 0.0156) and low-grade vs. high-grade ( = 0.0049) groups. No significant differences were identified in relation to dimc for the different degrees of dysplasia. For a cut-off point of 1.44 of dime, a specificity of 96.6% was obtained, a sensitivity of 100%, and an AUC = 0.819 ( = 0.003). FD at the level of the epithelium may be used as a diagnostic tool in OL.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14112697